| Record ID | marc_columbia/Columbia-extract-20221130-008.mrc:538756274:1702 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-008.mrc:538756274:1702?format=raw |
LEADER: 01702fam a2200397 a 4500
001 3977433
005 20221027012713.0
008 930428s1993 ne a b 101 0 eng c
010 $a 93008273
020 $a0444899871 (alk. paper)
035 $a(OCoLC)28116164
035 $a(OCoLC)ocm28116164
035 $9AHM3895HS
035 $a(NNC)3977433
035 $a3977433
040 $aDNLM/DLC$cDLC$dDLC$dNNC-M
050 00 $aRM322$b.N48 1993
060 00 $aW1 EP455KEA no.10 1993$aQV 85 N5317 1993
082 00 $a616.8/53061$220
245 00 $aNew antiepileptic drug development :$bpreclinical and clinical aspects /$cedited by Jacqueline A. French, Marc A. Dichter, Ilo E. Leppik.
260 $aAmsterdam ;$aNew York :$bElsevier,$c1993.
300 $axv, 255 pages :$billustrations ;$c27 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aEpilepsy research. Supplement,$x0920-1211 ;$vno. 10
504 $aIncludes bibliographical references and index.
650 0 $aAnticonvulsants$xTesting$vCongresses.
650 2 $aAnticonvulsants.$0https://id.nlm.nih.gov/mesh/D000927
650 2 $aClinical Trials as Topic.$0https://id.nlm.nih.gov/mesh/D002986
650 2 $aDrug Approval.$0https://id.nlm.nih.gov/mesh/D017277
655 2 $aCongress.$0https://id.nlm.nih.gov/mesh/D016423
700 1 $aFrench, Jacqueline A.$0http://id.loc.gov/authorities/names/n93801861
700 1 $aDichter, Marc A.$0http://id.loc.gov/authorities/names/n88046132
700 1 $aLeppik, Ilo E.$0http://id.loc.gov/authorities/names/n88046156
830 0 $aEpilepsy research.$pSupplement ;$vno. 10.$0http://id.loc.gov/authorities/names/n86713329
852 80 $boff,hsr$hSerial$iE